ALZECURE Aktie

>ALZECURE Performance

1 Woche: -0,4%

1 Monat: -15,8%

3 Monate: -21,6%

6 Monate: -47,2%

1 Jahr: -33,8%

laufendes Jahr: -21,6%

>ALZECURE Aktie

Name:

ALZECURE PHARMA AB

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0010133785 / A2N951

Symbol/ Ticker:

AC6 (Frankfurt)

Kürzel:

FRA:AC6, ETR:AC6, AC6:GR

Index:

Webseite:

https://www.alzecurepharm..

Profil:

Alzecure Pharma AB is a biopharmaceutical company engaged in the development of therapies for neurological disorders. Its primary focus is on generating innovative treatments that address significant unmet needs in areas such as Alzheimer's disease, ..
>Volltext..

Marktkapitalisierung:

17.85 Mio. EUR

Unternehmenswert:

13.47 Mio. EUR

Umsatz:

EBITDA:

-4.57 Mio. EUR

Nettogewinn:

-4.46 Mio. EUR

Gewinn je Aktie:

-0.04 EUR

Schulden:

0.24 Mio. EUR

Liquide Mittel:

4.72 Mio. EUR

Operativer Cashflow:

-3.24 Mio. EUR

Bargeldquote:

2.14

Umsatzwachstum:

Gewinnwachstum:

-35.13%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ALZECURE

Letzte Datenerhebung:

05.04.26

>ALZECURE Kennzahlen

Aktien/ Unternehmen:

Aktien: 114.91 Mio. St.

Frei handelbar: 71.75%

Leerverk. Aktien: -

Rückkaufquote: -28.62%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: 252.94%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 5.93

PEG-Ratio: -0.86

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -101.87%

Eigenkaprendite: -161.11%

>ALZECURE Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin, Alzheimer- Behandlung

>ALZECURE Chart & Kurs - Frankfurt
- Boerse Frankfurt
- >Profi Charts

>ALZECURE News

01.04.26 - 10:30	AlzeCure Pharma to Present at Redeye Alzheimer′s Theme Event on April 9 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusin......

19.03.26 - 08:36	AlzeCure Pharma: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer′s Conference AD/PD (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system,......

04.03.26 - 10:30	AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / March 4, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusin......

26.02.26 - 08:30	AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2025 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now availabl......

03.02.26 - 10:32	AlzeCure Pharma: AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer′s conference AP/PD 2026 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting th......

02.02.26 - 13:30	AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / February 2, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, f......

03.12.25 - 10:30	AlzeCure Pharma: AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer′s Disease (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous syste......

11.11.25 - 08:30	AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period Januar......

14.10.25 - 08:30	AlzeCure Pharma: Response Letter to Previous Article Published about Alzstatin′s Unique Mode of Action Against Alzheimer′s (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting th......

08.09.25 - 10:30	AlzeCure Pharma: Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, fo......

04.09.25 - 10:30	AlzeCure Pharma: Data from AlzeCure′s Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / September 4, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, fo......

26.08.25 - 08:30	AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2025 (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the comp......

20.08.25 - 10:30	AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focu......

19.08.25 - 10:30	AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focu......

05.08.25 - 10:30	AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focus......

29.07.25 - 08:30	AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusi......

24.07.25 - 11:30	AlzeCure Pharma: AlzeCure′s Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option (Accesswire)
	THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSS......

23.07.25 - 22:30	AlzeCure Pharma: AlzeCure′s Rights Issue Oversubscribed According to Preliminary Results (Accesswire)
	THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSS......

21.07.25 - 10:30	AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference (Accesswire)
	STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusi......

16.07.25 - 13:12	FDA grants orphan status for AlzeCure′s pain drug candidate (PBR)
	The company completed a positive Phase IIa trial of the candidate for chronic subjects with peripheral neuropathic pain. It is now preparing for further clinical development and has The post FDA grants orphan status for AlzeCure's pain drug candidate appeared first on Pharmaceutical Business review....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram